necessary
peh
expected
apply
considered
treated
kinetic
metaplasia
evaluation
umi
made
expressing
continue
undergoing
2012316
generalize
evolution
NO
reaction
cartilage
temerik
taxane
predicting
degree
2022
shokeir
assurance
perou
classify
surrounded
nlm
refer
apocrine
over
out
proportion
weighted
00289
briefland
TDU
subgroup
bentuk
solely
doe
schematic
bonferroni
outdated
RADS
multimodal
embase
descriptor
valid
assessment
benefit
1160
hypointensity
largest
corresponding
chondroid
eligible
1660
fig
eleonora
molekular
percutaneou
dynamic
78681
reagent
carried
e220151
longitudinal
positive
precision
activity
level
did
02334
21037
proteolysis19
wherea
genetic
pathological
continent
020
DBT
classified
anti
sincere
era
right
044
T1
arch
posterior
limfonodu
expres
divided
responsivenes
lako
nguyen
angulated
possible
fail
synthetic
span
suppression
measurement
breaast
retested
strategie
greater
later
etc
aromatase
acquisition
profile
pleomorphic
3390
woman
tega
algorithm
joo
guideline
identification
selected
pattern
radiological
reconstructed
hyperechoic
angular
histologic
concordance
org
resonance
tamoxifen
entire
10910
rycan
CT
timely
microcystic
twin
imaging
synthesizing
sought
presence
1161
chil
implication
hormone
analyzed
compiling
systemic
identifying
chemotherapy
representing
dxd
since
gene
109
1159
instead
found
epithelial
hypoechoic
view
variability
threat
cluster
iii
multifocal
function
omission
francesca
adenosquamou
solid
turn
myxoid
regulation
ER
pure
muzahir
africa
guided
focal
relation
magnetic
margin
radiologic
change
mpmri
anthracycline
explain
best
used
according
table
along
pioneering
protocol
human
included
create
identify
s12880
national
commonly
16607
TN
component
demonstrated
helpful
limitation
biological
85899
typically
xinmin
underserved
multisentri
elements11
mende
prerequisite
may
muslim
emerging
must
abnormalitie
worst
1174
described
randomized
pathologist
subtype
stroma
mortality
flow
data
lymphadenopathy
1170
understanding
ultrasound
visualization
department
step
enhancement
ha
useful
continuou
literature
estrogen
multisenstrisita
LIV1
resection
searche
value
hybridization
amplified
improved
aspiration
still
help
collect
managing
relationship
present
FCC
free
studie
saving
ductal
bordered
rhabdomyoid
integral
worldwide
index
society
processing
trial
backbone
side
MSI
our
205
morfologi
serie
capable
cancer
rank
expression
astute
different
integration
search
xie
WHO
clearly
neuroglial
influenced
background
D1
part
1171
cohort
within
journal
light
study
bang
seriou
8102
approache
ADC
raji
lobulated
CK8
investigate
scholar
her2neu
TOP2A
differentiated
through
oluwatosin
umberto
microscopy
predominantly
other
0477
suggested
hold
women
katharine
serrao
hormonal
testing
histopathological
differentiate
several
small
partly
les
NACT
labisso
evidence
edema
473
tested
dichotomou
com
eccentric
qiu
qualitative
enhance
fusion
observed
partially
further
lined
190
illustration
nor
histologically
regardles
HER2
making
ther
6th
ANDI
pathologic
161
partial
direction
some
research
involution
mean
SM
case
1007
round
panel
repeated
grade
neoadjuvant
rapid
tumor
median
show
maccio
using
echoe
her2th
220153
use
signature
therapy
residual
specific
region
squamou
nature
CK
clinically
low
wenjun
remain
mas
ex40
summarized
S2352
determining
minimized
another
laboratory
poorly
usually
s41598
alteration
contrast
added
predicted
makassar
associated
carcinoma
group
singly
photomicrograph
absorption
cystic
branching
ultrasonographic
apr
improving
european
fold
would
second
who
awarenes
good
leading
before
HER
due
prognosi
addition
victoria
grouped
masse
galati
diversity
ABLATIVE
progressively
copy
approved
care
offer
188
able
allow
BMC
tracer
digital
combating
irregularly
depict
distinctive
ESR1
trastuzumab
bhawna
promise
potentially
tomosynthesi
dilated
practice
iran
sunil
either
al5
malignant
above
1169
orcid
subtyping
developing
recommend
her2
gratitude
introduced
identified
reviewed
not
2214
unit
providing
varied
PIK3CA
interesting
US
ACR
jagged
1186
category
erth
direct
enriched
receptor
ijms242316607
pericannicular
risk
large
1080
independent
cytology
option
know
increased
toward
universita
activating
cell
fibroadenoma
accumulation
ineffectivenes
progression
neratinib
hoc
variable
lakhan
BLBC
tend
radiology
century
become
rim
worth
desmoplastic
population
linear
currently
positif
1097
early
about
necrosi
collection
tasked
alway
complexity
150
s00428
complete
nuclear
aim
signal
zhang
s43055
T4
septa
widely
serap
parameter
originate
clinician
kinase
image
future
horvath
radiologist
delay
1164
osteoid
january
translational
ready
maglione
immunophenotypic
immune
van
nano
technician
guo
qim
here
thereby
develop
public
latief
465
model
first
epithelium
survive
limit
term
evaluate
2017
library
organ
molecule
s41747
curve
morphology
overexpression
1038
also
lymph
update
error
zhu
vol
square
death
overall
examination
widespread
related
science
mccart
antibodie
topic
muscle
fulltext
histological
novel
12809
oval
characteristically
causing
density
edge
mol
skill
discussion
decreased
there
border
milk
farah
methodology
content
angiogenesi
selective
temporally
epidermal
broad
biopsie
respective
rely
PCOD
detection
membrane
mandatory
polycystic
assumption
outlined
interaction
yasmin
during
effort
without
published
high
course
increasingly
elsevier
exposed
criteria
ukuran
proposed
pathway
initial
TIL
cellular
gradually
dual
slide
microarray
hallmark
emarene
overview
well
diagnosi
recognized
dissection
nuclei
summary
recent
personalized
civil
based
bone
core
detecting
left
metaplastic
family
correlate
overlap
01087
established
bar
stinging
incidence
ray
medical
american
1166
histopathologic
radiol
enhancing
surrogate
center
unifocal
irregularitie
01206
lump
basic
trained
surgery
molecular
lexicon
approximately
complementary
therapeutic
controlled
shadow
combination
symptom
qualifie
SJ
example
ijradiology
multiple
107
CK18
drawn
shofiyah
focu
amplification
CAP
only
instrumentation
represent
proquest
grow
advanced
http
test
suggesting
damaged
google
multi
pmc
service
including
fall
particularly
seek
283
doctor
spindle
aided
ligand
escalation
misdiagnosi
expressed
skin
statistically
2019
indication
promising
seyfettin
S296784
ain
VOL
immunohistochemical
reject
reliable
each
familial
discrepancie
prepectoral
densitie
experimental
multicentricity
BCTT
simple
ASCO
ki67
shown
ntp
very
histotechnologist
NGS
needed
reported
laboratorie
drawing
purpose
herceptin
make
sub
dependency
capecitabine
2021
among
exist
diagnosed
nipple
genomic
moving
forty
assesment
arrow
0000
scale
radiographic
specimen
nigeria
ISH
parallel
prth
9144
shortening
activitie
reliably
increasing
rev
radiotherapy
two
characterize
influence
intralesional
intrinsic
microscope
spatio
better
disease
nih
gaining
painful
aberration
although
wajana
such
egyptian
labeling
combined
BIOENGINEERED
association
GATA4
figure
full
093
categorie
stained
effect
mutation
every
BC
2020
essential
while
include
routine
manner
intratumoral
adoption
faster
modality
history
consequently
varga
slow
minimally
immunotherapy
categorized
clustered
faculty
intelligence
T2
routinely
recapitulate
dogan
cost
health
MRI
mainly
newly
acros
modification
situ
distinguish
likewise
USG
almost
filed
0003
comparable
differentiating
financial
PPP4C
reproducibility
individual
AJR
development
efficacy
analyze
often
frequently
rahma
1172
lower
optimizing
professional
correction
dev
MD
stratification
zsuzsanna
nariya
predictive
prognose
statu
one
after
comparison
hyperintensity
smallest
require
BI
hyperplasia
duct
team
yang
detected
filled
adopted
kong
material
wang
BRCA
circumscribed
anatomy
application
likelihood
saima
given
western
histopathology
mohammed
decision
saharan
kim
monitoring
aggressive
expensive
pharmacological
range
explicit
separation
size
keyword
writing
assay
statistical
generally
showing
their
correlation
need
member
morphological
GEP
element
regarding
same
indicator
furthermore
voxel
into
few
17048
sequence
semiquantitative
showed
egfrth
reflect
multidisciplinary
unavoidable
proliferation
type
failure
reproducible
smooth
mildly
clear
multiparametric
indonesia
characteristic
external
spectroscopy
derutexan
information
interpreted
microcalcification
them
reduce
premature
adenopathy
delayed
valuable
medicina
1648
inflow
peningkatan
analysi
complex
sequencing
cerb
schnitt
szep
orientation
DWI
distinguished
southeast
s41392
alghazal
screening
field
propertie
invasively
distinct
suggest
limited
proliferative
occur
predominant
variou
third
neu
performed
together
massa
psychological
duration
mesenchymal
s12916
gov
report
secretion
followed
intermediate
prediction
plu
calcification
explore
mixed
E2F
introduction
hyperintense
provide
TDLU
CK7
acoustic
realizing
terminal
jun
024
blood
386
article
jwas_84_22
website
foundation
america
four
defined
distribution
physiological
clinical
however
rare
589
involve
stage
intensity
single
amy
eye
web
functional
quality
instability
available
give
602
03709
revealed
common
derived
challenge
relevance
contour
factor
112
gallen
22883
ejropen
septation
patient
biomarker
sequenced
hypothesized
reference
pertuzumab
sun
biopsy
source
sensitivity
breat
021
underwent
simulate
major
isoechoic
diagnose
topographic
RDE
suboptimal
role
uncalcified
www
programmed
mammogram
receiving
clonal
mimic
fast
especially
significant
PPP1CA
how
obtained
review
eva
peritumoral
proto
osseou
regular
othersubtype
1175
son
gland
even
consuming
protein
tinglin
traditional
technologie
lei
whose
collecting
commitment
spectrum
computer
1716
neither
setting
triple
pcr
PR
scheme
simin'
madalina
hkjr2217558
wa
lead
tenth
2018
ill
EGFR
modify
difficult
tailoring
liu
overexpressed
fibrocystic
node
shaped
refinement
enhanced
both
clustering
jing
chi
feature
growth
internal
pubmed
heterogeneou
microlobulated
accompanied
DOI
microsatellite
consist
HR
bilateral
art
response
conclusion
doi
korean
operator
time
accept
frequent
speculate
acknowledgement
subjectivity
ultrasonography
0687
2024
fine
targeted
undergo
6795
alone
ovarian
positively
jptm
percentage
marker
focused
defining
weight
target
classification
lack
DNA
five
performance
profiling
encode
progesterone
cochrane
recurrent
finding
ANOVA
chromosome
negative
cause
irregular
sample
wei
primary
avoidance
ISSN
structure
BRCA2
kalaw
64889
validation
having
learning
obtain
radilogy
amount
management
weak
sonographic
1173
blockade
when
score
possibly
biologically
presenting
ERBB2
moderate
modulator
potential
seven
they
eosinophilic
axial
jinwoo
PMC9536401
age
s12885
compared
1153
post
uncircumscribed
discussed
IHC
gambaran
heterologou
ongoing
endocrine
therefore
technical
reducing
abnormal
susceptible
growing
strong
repairing
confirmed
between
skewing
radiation
21655979
perception
minimum
could
T3
nanotechnology
persistent
metastatic
specialized
023
cho
state
life
complicated
conventional
like
noting
substantially
comprehensive
method
normal
than
challenging
regimen
increase
heterogeneity
washout
MR
diagnostic
most
interpretation
hong
BRCA1
NTRK
genotype
it
extension
but
set
non
extra
led
general
unresectable
replacement
wiley
consensu
detect
reveal
debilitating
ireguler
predict
p53
researcher
cannot
breast
conference
instrument
mdpi
2147
01366
three
highly
tissue
old
year
multicentric
lesion
asymmetry
evolve
AD
interchangeably
more
drug
reassessed
worse
needle
determined
1162
long
resistance
pathology
ncbi
rate
other'
correlating
roentgen
spiculated
demystifying
mammographic
poor
received
similar
young
comprise
procedure
limiting
artificial
why
outcome
essay
improve
3745
CC
harbor
technique
surgical
int
phenotype
radio
environmental
appear
section
subtipe
line
prevalence
accuracy
significance
differentiation
characterization
conducted
2015
result
invasive
cyst
descriptive
bata
benign
phase
perilesional
older
context
under
suffer
0000000000028621
insight
tool
erb
rounded
underrepresented
author
unenhanced
provided
alternative
exhibit
fibromatosi
modalitie
methodologie
1148
ovary
100
particular
follow
quantitative
2023
north
inhibitor
overcome
appropriate
1163
survival
345
approach
tyrosine
amounted
adult
jwa
lawsuit
experience
today
possibility
4132
shape
dilatation
medicine
evaluating
TNBC
lobular
replace
note
many
feasibility
being
immunohistochemistry
difference
proces
monoclonal
prognostic
anatomic
2013
mixture
cystically
ability
cyclin
unisentri
authoritie
sampling
higher
PPPC
asses
certain
oncogene
previou
114
cheang
mammary
positivity
CNR
akinnibosun
1165
022
behave
investigated
longer
processe
sci
formation
fully
absence
quite
00040
safaa
ximin
staging
perform
invisible
axillary
current
way
1168
jinwoo'
stiffnes
mammography
point
should
hafsat
basal
suspiciou
al2
radiomic
determine
negatif
adjuvant
overexpressing
important
deep
dose
1167
system
therapie
enchance
international
treatment
investigation
advance
pictorial
cytokeratin
slight
sham
appearing
00999
larger
insurance
systematic
least
will
all
specificity
actively
4103
because
scopu
number
characterized
luminal
tailor
significantly
thi